Form 4: Mira Pharmaceuticals Director Michael Jerman Acquires 50,000 Stock Options
SEC Form 4 Filing
Michael Jerman, a director at Mira Pharmaceuticals, acquired 50,000 nonqualified stock options on March 25, 2024, with half vesting immediately and the remainder vesting in one year.
Summary
- On March 25, 2024, Michael Jerman, a director of Mira Pharmaceuticals, acquired 50,000 nonqualified stock options.
- The exercise price of these options is $1.16.
- 25,000 of these options vested immediately on the grant date.
- The remaining 25,000 options will vest on March 25, 2025.
- The options expire on March 25, 2034.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a standard disclosure of stock option grants, which is neither overtly positive nor negative.
Positives
- The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.
Future Outlook
The document does not contain specific forward-looking statements beyond the vesting schedule of the options.
Industry Context
This filing is a routine disclosure related to executive compensation and is common in the pharmaceutical industry.
Stakeholder Impact
- The granting of stock options aligns the director's interests with those of the shareholders, potentially encouraging decisions that increase shareholder value.
Key Dates
| Date | Description |
|---|---|
| 03/25/2024 | Date of earliest transaction: Grant date of 50,000 nonqualified stock options, with 25,000 vesting immediately. |
| 03/25/2025 | Vesting date for the remaining 25,000 stock options. |
| 03/25/2034 | Expiration date of the 50,000 nonqualified stock options. |
| 03/27/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.